clinical trials

The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities

ABSTRACT Topical formulations that contain cannabinoid ligands (or that enhance the cutaneous ECS tone) could have therapeutic values in skin inflammations. Indeed, recently, a new drug containing PEA has been approved by the FDA for the treatment of dermatitis [70]. Moreover, a recent pilot study on 20 pediatric patients suffering from atopic dermatitis aimed to …

The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities Read More »

Cannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders?

ABSTRACT Movement disorders such as Parkinson’s disease and dyskinesia are highly debilitating conditions linked to oxidative stress and neurodegeneration. When available, the pharmacological therapies for these disorders are still mainly symptomatic, do not benefit all patients and induce severe side effects. Cannabidiol is a non-psychotomimetic compound from Cannabis sativa that presents antipsychotic, anxiolytic, anti-inflammatory, and …

Cannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders? Read More »

Scroll to Top
Scroll to Top